Source: Virtual Congress 2021 – Therapy of lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
M. Hamdi (Ariana, Tunisia), F. Chermiti (Ariana, Tunisia), B. Nidhal (Ariana, Tunisia), B. Imen (Ariana, Tunisia), F. Soraya (Ariana, Tunisia). Does long treatment delay affect survival in metastatic non-small cell lung cancer. 2309

Member's Comments

No comment yet.

Related content which might interest you: The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Does the lung function affect the survival time in patients with resected non-small cell lung cancer? Source: Annual Congress 2007 - Lung function parameters before and after thoracic surgery Year: 2007 Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient Source: Eur Respir J 2015; 46: 280-282 Year: 2015 Time trends in treatment and survival of non-small cell lung cancer in The Netherlands Source: Annual Congress 2010 - Quality management for lung cancer patients Year: 2010 The impact of neuroendocrine differentiation in the prognosis of non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Effects of pretreatment prognostic factors and treatment on survival in advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003 Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Characteristics and survival analysis of synchronous oligometastatic non-small cell lung carcinoma. Source: Virtual Congress 2020 – Localised non-small cell lung cancer Year: 2020 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 One year survival differences of EGFR- and KRAS-mutated advanced non-small cell lung cancer (NSCLC) compared to the wildtype population Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)? Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 Carbohydrate-induced conformational MUC1 tumor-epitope correlates with improved post-surgical survival of non-small cell lung cancer patients with local or distant metastasis Source: Eur Respir J 2006; 28: Suppl. 50, 150s Year: 2006 Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma Source: Annual Congress 2009 - Lung cancer biology Year: 2009